On a recent July afternoon, a group of residents at the Hebrew Home of Riverdale, New York congregated on a shady terrace. They were sitting in a semicircle facing Deborah Michaels, the instructor leading the yoga class. “Okay now we’re going to lift our hands up,” Michaels said. The participants raised their arms, some more than others. “And gently back down.” Michaels continued running through the basics of a yoga class, modified to be done while seated, for another half-hour. Yoga classes run twice per week, and are part of a larger strategy at the Hebrew Home to use alternative techniques in treating residents in their memory care unit.
Nearly one in three seniors suffer from some form of dementia, with Alzheimer’s being the most common. The neurodegenerative disease has been declared the sixth-leading cause of death in the United States. Perhaps most troubling to many is the fact that unlike cancer or AIDS, little is understood about the true pathology and direct causes of Alzheimer’s, including genetic risk factors. Detection and prevention are seldom options. Mitigating the effects of the disease with physical exercise has become a growing trend in the care and treatment of Alzheimer’s patients.
Several studies have examined a possible genetic link to Alzheimer’s, but few focus on Ashkenazi Jewish heritage specifically. The only firm links have been found in the early-onset form of the disease, which affects people under the age of 65 and accounts for only 5% of all Alzheimer’s cases. “You have this classic inheritance pattern from the disease, families where it appears to be endemic,” explains Dr. Lindsay Farrer of the Boston University Alzheimer’s Disease Center. Roughly 200 extended families worldwide carry this genetic mutation, among them an extended family of Ashkenazi Jews in the United States that was the subject of extensive study in the 1980s. As chronicled in the book “Hannah’s Heirs,” family members tracing medical records back to the early 19th century were able to narrow down the single ancestor from which their early-onset gene emerged.
One of the very few studies focusing explicitly on Jews, published in the Journal of the American Geriatrics Society in 2000 looked only at a very specific genetic mutation in a small population. Farrer explains that with genetic mutations of this sort, “the story is fairly checkered.” So far, while strong genetic risk factors for Alzheimer’s are prevalent among Ashkenazi Jews, no literature points to anything unique, according to Farrer.
Farrer was involved in one of the earliest Alzheimer’s studies to make a breakthrough. In 1995, his team discovered the presenilin-1 gene, which has been directly linked to the production of the protein beta amyloid, viewed as a major culprit in the onset of Alzheimer’s. Like a clogged pipe, plaque buildup caused by beta amyloid disrupts communication between brain cells. As plaque builds up, more brain functions are affected; memory loss, motor function decline and lack of ability to communicate are frequently associated with the disease precisely for this reason.